ADORA3 and fibrosis: In summary, LJ-4459, a new dual-acting agent that acts as both an A2AAR agonist and an A3AR antagonist, effectively prevented obstruction-induced kidney dysfunction, inflammation, tubulointerstitial fibrosis, and oxidative stress.